Dual antibody A

Dual antibody A is an investigational therapeutic agent referred to as a "dual antibody," which suggests it is engineered to target two different antigens or pathways. It is currently being studied as part of enhanced adjuvant therapy regimens for patients with newly diagnosed glioblastoma multiforme (GBM) following partial surgical resection or in cases of short-term progression. The precise targets and mechanisms of action of Dual antibody A are not specified in the publicly available data, but dual antibodies typically exert their effects by binding simultaneously to two different molecular targets, potentially improving efficacy over single-target agents[4][5].

Brand names

Dual antibody A

Other names

Dual antibody A